A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
Status:
Not yet recruiting
Trial end date:
2023-04-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the amount of PF-07081532 in blood after taking two
different forms of PF-07081532. This study is seeking participants who are at least 18 years
of age and are overweight and/or obese. All study participants will receive a total of 2
single doses of this study medication in either form. Form A consists of a PF-07081532 20 mg
immediate release tablet and a PF-07081532 60 mg immediate release tablet. Form B consists of
a PF-07081532 80 mg immediate release tablet. Each single dose will be separated by a minimum
of 6 days. The amount of PF-07081532 in the blood for 4 days after taking each single dose
will be compared between the two different formulations of PF-07081532.
The total time that participants will take part in this study is about 70 days. The first
visit is a screening visit to ensure that participants are appropriately qualified for the
study. This will occur up to 28 days before the first single dose. Participants will be
admitted into the clinic one day prior to the first single dose and will remain in the clinic
for a total of 11 days. The study team will phone the participants 28 to 35 days after the
last dose of study medication.